Carnegie Investment Counsel Has $49.83 Million Stake in Zoetis Inc. $ZTS

Carnegie Investment Counsel lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 340,532 shares of the company’s stock after purchasing an additional 21,563 shares during the quarter. Zoetis accounts for about 0.9% of Carnegie Investment Counsel’s portfolio, making the stock its 23rd biggest position. Carnegie Investment Counsel owned about 0.08% of Zoetis worth $49,827,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ZTS. Nova Wealth Management Inc. acquired a new stake in Zoetis during the 1st quarter worth approximately $25,000. Halbert Hargrove Global Advisors LLC increased its position in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares in the last quarter. 1248 Management LLC bought a new stake in shares of Zoetis during the first quarter worth $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis during the first quarter worth $29,000. Finally, REAP Financial Group LLC lifted its position in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a report on Monday, December 15th. KeyCorp assumed coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating for the company. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday. UBS Group reduced their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Finally, Morgan Stanley set a $160.00 price target on shares of Zoetis in a research note on Thursday, December 18th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $160.18.

Zoetis Stock Up 0.5%

ZTS stock opened at $126.16 on Friday. The company has a market cap of $55.60 billion, a price-to-earnings ratio of 21.24, a P/E/G ratio of 2.73 and a beta of 0.97. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.40. The business has a 50 day moving average price of $127.05 and a two-hundred day moving average price of $143.14. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the prior year, the firm posted $1.58 EPS. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be given a $0.53 dividend. This is a boost from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s payout ratio is 33.67%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.